Meletios Therapeutics develops broad-spectrum antiviral molecules, including host-targeting agents and defective viral genomes, to address the urgent need for effective treatments against current and emerging viral infections. Their drug candidates aim to provide rapid therapeutic options for patients during viral pandemics, minimizing the risk of treatment resistance.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antiviral treatments often target specific viruses and may not be effective against emerging or rapidly evolving viral infections. The development of resistance to narrow-spectrum antivirals poses a significant challenge, necessitating the creation of broad-spectrum therapies. There is a need for treatments that can address viral infections regardless of the specific strain causing the pandemic.
Solution
Meletios Therapeutics is developing broad-spectrum antiviral therapies designed to combat a wide range of current and emerging viral infections. Their approach focuses on preventing viruses from utilizing host resources through two complementary strategies: host-targeting agents and defective viral genomes (DVGs). The DVG platform, originating from the Institut Pasteur, uses RNA sequences to interfere with the protein expression machinery hijacked by viruses. Their lead drug candidate, MLT103, is a host-targeting agent with immunomodulatory activity, aimed at treating inflammation dysregulation in respiratory viral infections.
Target Audience
The primary target audience includes patients at risk of or infected with viral diseases, as well as healthcare providers and public health organizations seeking broad-spectrum antiviral solutions for pandemic preparedness.
Features
- Defective Viral Genome (DVG) platform that disrupts viral protein expression
- Host-targeting agents that target metabolic resources hijacked by viruses
- MLT103, a lead drug candidate, demonstrates immunomodulatory activity in respiratory viral diseases
- Biomarkers predictive of viral diseases
- RNA virus agnostic platform with the capacity to generate DVG candidates within months